The FDA’s Priority Review designation allows for a shortened review period (within 6 months) from the time of application acceptance.

The Food and Drug Administration (FDA) has granted accelerated approval to Voyxact ® (sibeprenlimab-szsi) to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk for ...

GLP-1 RA use with subsequent prepregnancy or early pregnancy discontinuation linked to higher risk for preterm delivery, gestational diabetes ...

March of Dimes report shows high rates of preterm birth, infant mortality, as well as worsening sociodemographic disparities.

Association strongest for those with cannabis use disorder compared with cannabis users without abuse or dependence or nonusers.